TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

7.171 Stevens DA et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007;132: 952-8. 7.172 Anstead GM et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40:1770-6. 7.173 Catanzaro A et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007;45:562-8. 7.174 Liliang PC et al. Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus negative patients. Clin Infect Dis 2003;37:673-8. 7.175 Cortez KJ et al. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003;36:1619-22. 7.176 Proia LA et al. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004;48:2341. 7.177 Johnson RH et al. Coccidioidal meningitis. Clin Infect Dis 2006;42:103-7. 7.178 Stevens DA et al. Posaconazole for chronic refractory coccidioidomycosis. Chest 2007;132:952-8. 7.179 Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322. 7.180 Perfect JR. Management of cryptococcosis: how are we doing? PLoS Med 2007;4:e47. 7.181 Saag MS et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000;30:710-8. 7.182 Chayakulkeeree M et al. Cryptococcosis. Infect Dis Clin North Am 2006;20:507-44. 7.183 Lindberg J et al. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect Dis 2007;13:178-9. 7.184 Park MK et al. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999;28:629-33. 7.185 Horcajada JP et al. Invasive cryptococcosis and adalimumab treatment. Emerg Infect Dis 2007;13: 953-5. 7.186 Khawcharoenporn T et al. Treatment of cryptococcosis in the setting of HIV coinfection. Expert Rev Anti Infect Ther 2007;5:1019-30. 7.187 Bicanic T et al. Cryptococcal meningitis. Br Med Bull 2004;72:99-118. 7.188 Dromer F et al. Epidemiology of HIV associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004;18:555-562. 7.189 Brouwer AE et al. Combination antifungal therapies for HIV associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7. 7.190 Sun HY et al. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009;48:1566-76. 7.191 Jarvis JN et al. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 2008;21:596-603. 7.192 Baddour LM et al. Succesful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005;40(suppl. 6):S409-13. 7.193 Singh N et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008;46:e12-8. 7.194 Couppié P et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis 2004;38:134-8. 7.195 Pappas PG et al. Recombinant interferon-γ1b as adjunctive therapy for AIDS related cryptococcal meningitis. J Infect Dis 2004;189:2185-91. 7.196 Pitisuttithum P et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55. 7.197 Bicanic T et al. Fungal burden, early fungicidal activity, and outcome of cryptococcal meningitis in antiretroviral-naïve or antiretroviral experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80. 7.198 Lortholary O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. Clin infect Dis 2007;45:81-3. 7.199 Bicanic T et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43:1069-73. 7.200 Sungkanuparph S et al. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr 2007;45:595-6. 7.201 Woodworth GF et al. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegaly secondary to HIV associated cryptococcal meningitis. Surg Neurol 2005;63:529-32. 7.202 York J et al. Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution inflammatory syndrome or recurrent cryptococcal disease? J Infect 2005;51:165-71. 7.203 Schwartz RA. Superficial fungal infections. Lancet 2004;364:1173-82. 7.204 Gupta AK et al. Optimal management of fungal infections of the skin, hair and nails. Am J Clin Dermatol 2004;5:225-37. 7.205 Chang CH et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007;120:791-8. 7.206 Degreef H. Clinical forms of dermatophytosis (ringworm infection). Mycopathologia 2008;166:257- 65. 7.207 Fuller LC. Changing face of tinea capitis in Europe. Curr Opin Infect Dis 2009;22:115-8. 7.208 Kalivros A et al. Tinea capitis in Brussels: epidemiology and new management strategy. Dermatology 2003;206:384-7. 7.209 Sigurgeirsson B et al. Long term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis. Arch Dermatol 2002;138:353-7. 7.210 Havu V et al. A double blind, randomized study to compare the efficacy and safety of terbinafine with fluconazole in the treatment of onychomycosis. Br J Dermatol 2000;142:97-102. 7.211 de Berker D. Fungal nail disease. N Engl J Med 2009;360:2108-16. 7.212 Gupta AK et al. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008;166:353-67. 7.213 Gupta AK et al. Therapies for onychomycosis: a review. Dermatol Clin 2006;24:375-9. 7.214 Gupta AK et al. Onychomycosis therapies: strategies to improve efficacy. Dermatol Clin 2006;24: 381-6. 7.215 Gupta AK et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toe-
nail onychomycosis. J Eur Acad Dermatol Venereol 2009;23:256-62. 7.216 Piraccini BM et al. Long term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010;62:411-14. 7.217 Daniel CR et al. The illusory tinea unguium cure. J Am Acad Dermatol 2010;62:415-7. 7.218 Baran R et al. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005;19:21-9. 7.219 Roberts DT et al. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10. 7.220 olde Hartman TC et al. Fungal nail infection. Br Med J 2008;337:295. 7.221 Gupta AK et al. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004;150:537-44. 7.222 Gupta AK. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002;16:19-33. 7.223 Gupta AK et al. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother 2005;6:165-78. 7.224 Rezusta A et al. Tinea nigra: a rare imported infection. J Eur Acad Dermatol Venereol 2010;24:89- 90. 7.225 Nucci M et al. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007;20: 695-704. 7.226 Nucci M et al. Cutaneous infection by Fusarium in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002;35:909-20. 7.227 Ho DY et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50:227-31. 7.228 Dignani MC et al. Human fusariosis. Clin Microbiol Infect 2004;10(suppl. 1):67-75. 7.229 Raad II et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403. 7.230 Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 7.231 Lewis JS. Therapeutic drug monitoring of antifungal agents. Curr Fungal Infect Rep 2009;3:96-102. 7.232 Trifilio S et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. 7.233 Wheat LJ et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807-25. 7.234 Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007;20:115-32. 7.235 Kauffman CA. Endemic mycoses: blastomycosis, histoplamosis, and sporotrichosis. Infect Dis Clin North Am 2006;20:645-62. 7.236 Adderson E. Histoplasmosis. Pediatr Infect Dis J 2006;25:73-4. 7.237 Gutierrez ME et al. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis 2005;40:1199-202. 7.238 Wheat LJ et al. Histoplasmosis. Infect Dis Clin North Am 2003;17:1-19. 7.239 Johnson PC et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002;137: 105-9. 7.240 Hajjeh RA et al. Multicenter case control study of risk factors for histoplasmosis in human immunodeficiency virus infected persons. Clin Infect Dis 2001;32:1215-20. 7.241 Couppié P et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis 2004;38:134-8. 7.242 Cuellar-Rodriguez J et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009;49:710-6. 7.243 Hage CA et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010;50:85-92. 7.244 Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 2008;21:421-5. 7.245 Wheat LJ et al. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005;40:844-52. 7.246 Wheat LJ et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001;33: 1910-3. 7.247 Spellberg B et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009;48:1743-51. 7.248 Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008;61 (suppl. 1):i35-9. 7.249 Chayakulkeeree M et al. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25:215-29. 7.250 Bouza E et al. Mucormycosis: an emerging disease? Clin Microbiol Infect 2006;12(suppl. 7):7-23. 7.251 Kontoyiannis DP et al. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006;20:581-607. 7.252 Zaoutis TE et al. Zygomycosis in children: a systematic review and analysis of reported cases in children. Pediatr Infect Dis J 2007;26:723-7. 7.253 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.254 Spellberg B et al. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005;18:556-69. 7.255 Roden MM et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53. 7.256 Safar A et al. Early identification of rhinocerebral mucormycosis. J Otolaryngol 2005;34:166-71. 7.257 Mantadakis E et al. Clinical presentation of zygomycosis. Clin Microbiol Infect 2008;15(suppl. 1):15-20. 7.258 Greenberg RN et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004;17:517-25. 7.259 Skiada A et al. Cutaneous zygomycosis. Clin Microbiol Infect 2009;15(suppl. 1):41-5. 7.260 Roilides E et al. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2008;15 (suppl. 1):50-4. 7.261 Petrikkos GL. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect 2009;15(suppl. 1):87-92. 7.262 Chamilos G et al. Delaying amphotericin B-based frontline therapy significantly increases mortality
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49: 7.121 Walsh TJ et al. All catheter
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?